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Summary
Background: With an annual incidence of 0.2% of new
cases per 100,000 inhabitants, adrenocortical carcinoma
is rare. In advanced tumor only palliative treatment
modalities are practicable. Because of scarcity of the
tumor, standard treatment has not been defined. The
decision on therapy frequently depends on the individual
situation. Tumor embolization and chemotherapy are
amongst the possible options. Patient and Methods: We
report on a case of a 32-year-old female patient with 
a large-volume hormonally active adrenocortical car-
cinoma and hematogenous liver metastases. This car-
cinoma was confirmed histologically by means of liver
biopsy. Owing to the large tumor extent and metastatic
spreading and also in view of the poor general condition
of the patient, curative surgical therapy was not possible.
For this reason, a local approach was chosen primarily
with transarterial tumor embolization at the capillary
level. Systemic chemotherapy was given afterwards.
Results: Improvement of the patient’s general condition,
especially the pronounced pain symptoms, could be
achieved for a short time by the embolization: both, the
patient’s clinical condition and the laboratory test pa-
rameters improved. However, a rapid tumor progression
occured under chemotherapy, which was started after
embolization. Conclusion: In advanced adrenocortical
carcinoma, tumor embolization can lead to a stabilization
of the disease and improvement of the symptoms as
appraised by palliative criteria in some patients.
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Zusammenfassung
Hintergrund: Das Nebennierenrindenkarzinom zählt mit
einer jährlichen Inzidenz von 0,2% Neuerkrankungen pro
100.000 Einwohnern zu den seltenen Malignomen. In fort-
geschrittenen Tumorstadien und bei chirurgisch nicht
resektablen Tumoren kommen nur palliative Therapie-
ansätze zum Einsatz. Aufgrund geringer Fallzahlen liegen
wenige Studien und somit keine Standardtherapiever-
fahren vor. Die Therapieentscheidung richtet sich häufig
nach der individuellen Einzelsituation, wobei Tumor-
embolisation und Chemotherapie zu den möglichen
Optionen zählen. Patient und Methoden: Wir berichten
über den Fall einer 32jährigen Patientin mit einem
großvolumigen, hormonaktiven Nebennierenrindenkarzi-
nom und hämatogener Lebermetastasierung. Das Karzi-
nom wurde histologisch mittels Leberbiopsie gesichert.
Aufgrund der großen Tumorausdehnung, der Metastasie-
rung und des schlechten Allgemeinzustandes der Patien-
tin war eine kurative chirurgische Therapie nicht möglich.
Deshalb wurde primär mit der transarteriellen Tumor-
embolisation auf Kapillarebene ein lokales Vorgehen
gewählt. Im Anschluß erfolgte eine systemische Chemo-
therapie. Ergebnisse: Durch die Embolisation ließ sich
klinisch und laborchemisch für kurze Zeit eine Besserung
des Allgemeinbefindens, insbesondere der ausgeprägten
Schmerzsymptomatik, erzielen. Dieser deutlich nachweis-
bare Effekt ist auch histopathologisch belegbar. Ein er-
neuter, rascher Tumorprogreß konnte auch durch die
dann eingeleitete systemische Chemotherapie nicht mehr
beeinflußt werden. Schlußfolgerung: Bei fortgeschrit-
tenem Nebennierenrindenkarzinom kann die Tumor-
embolisation unter palliativen Gesichtspunkten zu einer
Krankheitsstabilisierung und Besserung der Beschwerden
einzelner Patienten führen.
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Introduction
Adrenal cortical carcinomas are rare tumors, with an estimated
annual incidence of 0.5–2 / 1 million population [1]. In principle,
functional and nonfunctional tumors can be distinguished.
Accordingly the clinical symptoms depend on the differentia-
tion of the adrenocortical function (e.g. Cushing’s syndrome
and primary hyperaldosteronism, hirsutism, virilization or
feminization).
Life expectancy of patients is short and depends on the tumor
stage at diagnosis. The poor prognosis can be improved by
early diagnosis and radical primary operation.According to De
Vita et al. [2], most patients (70%) present in the advanced
tumor stage III or IV at diagnosis, i.e. they show a tumor with
local infiltration and/or positive lymph nodes or additional
metastatic spreading.
In principle, the primary options for treatment comprise local
measures such as surgery [3, 1, 4] as the sole possibility of cure,
embolization [5, 6], and local radiation [7]. In locally very
advanced disease and metastatic spreading, systemic treatment
such as antihormonal therapy or chemotherapy may be used
for palliative purposes.
We report a patient with advanced, metastasized adrenal cor-
tical carcinoma and a prominent symptomatology as defined
by a very pressure-dolent abdomen and the possibility of
tumor embolization as a palliative therapy modality.
Case Report
A 32-year-old female patient in whom weight gain of 20 kg had been
noticed over 1 year was admitted. In addition, there had been signs of viril-
ization, secondary amenorrhea and leg edema for a few months.
Primary diagnostics were carried out at her local hospital by means of
abdominal sonography and computer tomography (CT) and showed a
space occupation of 11.5 · 10 cm in the region of the right adrenal. In addi-
tion, bilobular multiple hepatic metastases of varying sizes could be
demonstrated. A liver focus was biopsied for further clarification. Histo-
logical and immunohistochemical appraisal elsewhere revealed a clear cell
carcinoma corresponding to a metastasis of an adrenocortical carcinoma.
For further diagnostics and treatment, the patient was transferred to our
hospital. On physical examination, we found a very adipose patient with a
reduced general condition. She was hypertensive with blood pressure
values up to 160/105 mmHg and a heart rate at 80/min. In addition to the
initial admission, as described above, a pressure-dolent abdomen with
distinct guarding was very prominent. Besides, she reported on severe
attacks of anxiety. At the same time, she was suffering from depression.
A current computer tomography showed a distinct progression in terms 
of size of the primary tumor and the liver metastases. By angiographic
examination infiltration of the kidney could be ruled out. In addition,
pulmonary and skeletal metastases could be excluded. There were patho-
logical changes in the clinical test parameters: LDH (4263 U/l), potassium
(2.8 mmol/l) and aldosterone (963 pg/dl, normal 30–160 pg/dl), cortisol
(76.8 µg/dl, normal 15–25 µg/dl), androstendione (>10.0 ng/ml, normal
1.0–4.4 ng/ml) and DHEA-S (dehydroepiandrosterone sulfate; >10.0 µg/
ml, normal 0.8–3.4 µg/ml). The synthetic liver activity was normal apart
from lowered total protein (4.9 g/dl) and albumin (2.2 g/dl). In particular,
ammonia and lactate were in the normal range.
Furthermore, the excretion of DHEA-S and the corresponding metabo-
lites as well as THS (11-deoxy-tetrahydrocortisol) in the urine were exces-
sively raised.
Clinical Course
The patient had an advanced hormonally active adrenocortical
carcinoma (tumor stage T3 N1 M1, corresponding to clinical
stage IV) with hepatic metastases. A local surgical procedure
was not possible because of the tumor size and the pronounced
hepatic metastases. Moreover, the general condition of the
patient was greatly reduced. In view of the already poor liver
function, we used ketoconazole to block steroid synthesis. The
potassium level could be raised to the normal range by substi-
tution and administration of an aldosterone antagonist.
Because of this palliative situation, a local treatment measure,
namely regional embolization, was chosen primarily with the
objective of rapid alleviation of pain and the abdominal ten-
sion. Therefore transvascular embolization, with a total of 
11 ml ethibloc administration, was carried out in the same 
session with the diagnostic angiography. Following repeated
computer tomographic checks did not show any criteria for
inflammation or perforation.
After the embolization a pronounced alleviation of the pain
and improvement of the general condition of the patient was
significant. This clinical condition was stable for about 10 days.
In this short phase, there was also an impressive brightening of
the initially depressive mood.
Then renewed clinical and laboratory test values rapidly dete-
riorated. This correlated with an explosive increase in size of
the nonembolized metastases in both liver lobes. Systemic
chemotherapy was then started with 100 mg etoposide i.v. and
300 mg carboplatin i.v., but had to be discontinued because of
a fulminant kidney failure, respiratory deterioration, and som-
nolence of the patient. The patient died of multiorgan failure
with massive tumor progression and the clinical suspicion of
sepsis.
At autopsy, a metastasized right adrenocortical carcinoma was
found (weight 460 g, size 17 · 9 · 7 cm) with multiple liver me-
tastases (up to 5 cm in diameter) and a high degree of hepato-
megaly (weight 4650 g). Considering the embolization, a vessel
branch of the cranial renal artery, leading to the cranial pole of
the tumor was obliterated by embolization material up to the
peripheral vascular bed. The cranial part of the tumor showed
extensive necroses up to 8.5 cm in diameter (fig. 1). The right
hepatic artery was also obliterated in its entire course up to the
arteries of the portal fields (fig. 2). The right liver lobe showed
a pronounced parenchymal necrosis (15 cm in diameter).
Discussion
The prognosis of the adrenocortical carcinoma is unfavorable
and mainly depends on the tumor stage at the time of diagnosis
[8, 9]. Only in early stages surgery can result in constant cure.
The median survival time for stages III and IV is 0.6 years [10].
The disease is often diagnosed in advanced stage and for this
therapy modalities frequently published report on individual
experience or illustrate patient groups which are heteroge-
neous with regard to the tumor stages, so that no generally
valid treatment protocols have been described [3, 2]. In case of
inoperability, alternative treatment remains only palliative, e.g.
chemotherapy, radiation or other local procedures. Intraarterial
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embolization with lipidol or ethibloc, which causes ischemic
necrosis of the tumor, has been used as palliative treatment
either alone or in combination (chemoembolization).The com-
bination, described often as therapy for hepatocellular carci-
noma, is very toxic and did not significantly improve survival.
Embolization is considered as very effective on the basis of
reports of a rapid decrease in tumor size [11].
Therefore, in the reported case tumor embolization was chosen
as first therapy, especially because a rapid clinical effect could
be expected, although it was quite sure that it might not have a
positive effect on survival, but might improve the quality of
life. To avoid toxicity in a situation with diffuse hepatic metas-
tasis the embolization was performed without the combination
with chemotherapy.The latter should be performed as systemic
modality in a second step. Because of the great overall extent
of the tumor, radiation with a justifiable radiotherapeutic
target volume was not practicable.
The indication and methodological procedure of tumor embo-
lizations have been discussed in many reports [12, 5]. Kauff-
mann and Richter [5] make special reference to the selection
and the methodological procedure in tumor embolization.
Ethibloc, which consists of zein (a gelatinous maize protein), is
appropriate when, like in this case, a homogeneous occlusion
of the capillary vascular compartment, is intended.The mecha-
nism of occlusion is based on precipitation of the gel in the
blood and on controlling the embolization plane with alcohol
and glucose, which were added to the solvent. A distinct pe-
ripheral to capillary occlusion type results without the danger of
venous dissemination, which is shown in the histological prep-
aration of the liver metastasis of the reported patient (fig. 2).
Systemic treatment is indicated in failure of local measures or
tumors which are primarily inoperable or cannot be otherwise
approached regionally, and in metastatic spreading. Most ex-
perience is available with mitotane (o,p’-DDD), especially in
hormone-producing tumors. The substance has been devel-
oped from the insecticide DDT and is characterized by a high
adrenolytic action. However, mitotane is considered to have
many side effects and therefore often cannot be given in maxi-
mum doses [13].
Ketokonacol, aromatase inhibitors (e.g. aminogluthetimide) 
[2, 10] and suramin are available for isolated antihormonal
purposes. These substances primarily alleviate the clinical
symptoms resulting from hormone overproduction. Objective
remissions, such as have been described for mitotane under 
a standard dosage (6–10 g/day) with 20–25% [14], are not
expected.
Besides the substances specified, classical chemotherapy can
also be employed in advanced metastasized adrenocortical car-
cinoma. Doxorubicin, BCNU, 5-fluorouracil and methotrexate
appear to be effective single substances [2, 15]. An action on
the tumor in adrenocortical carcinoma is also ascribed to cis-
platin, especially in combination treatments. A remission rate
of 23% could be attained under therapy with cisplatin, doxo-
rubicin and 5-fluorouracil. These series included 1 patient with
a complete remission persisting for 4 years [10]. After admini-
stration of cisplatin, etoposide and bleomycin, 2 out of 4 pa-
tients attained a remission [16]. An overall response rate of
53.5% could be achieved by combining mitotane with the
cytotoxic drugs etoposid, doxorubicin, and cisplatin [17].
In a case report, Zidan et al. [18] reported on the response of a
female patient with liver metastases after 5 cycles of chemo-
therapy with cisplatin and etoposide. The remission was main-
tained for 17 months; surgical resection of the liver metastases
was carried out after the end of cytostatic therapy [18]. Other
study groups also confirmed tumor regression under this com-
bination of cytostatics [19]. By analogy, we chose the more
recent derivative carboplatin as a less nephrotoxic substance.
The combination of carboplatin with etoposide appeared
appropriate, since positive experience is also available with
other tumor diseases which are primarily refractive in indi-
vidual cases such as small-cell lung cancer, germinal cell
tumors, and neuroendocrine neoplasias [20, 21]. Because of the
impressive clinical improvement after the embolization, there
was made the decision for systemic chemotherapy at time of
progression of the nonembolized liver metastasis.
The rapid further progression of the tumor with simultaneous
clinical deterioration compelled us to discontinue chemothera-
py before its completion, so in the case presented no appraisal
can be made with regard to response to this treatment. It can-
not be excluded that the chemotherapy played an additional
role in the described organ failure. Our positive interim expe-
Fig. 1: Autopsy finding: Preparation of the adrenocortical carcinoma.
Fig. 2: Autopsy finding: Histology of a portal field, embolization material
in the artery stained brown (eosin-von Gieson, magnification · 100).
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rience concerned the therapeutic use of embolization. We con-
clude that tumor embolization could be an effective method to
improve the quality of life in patients with an isolated symp-
tomatic inoperable tumor or with isolated metastasis. In the
case discussed above this effect was limited early by the rapid
progress of the diffuse liver metastasis.
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